S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?

Exact Sciences (EXAS) Stock Forecast & Price Target

$56.31
-0.59 (-1.04%)
(As of 02/28/2024 ET)

Exact Sciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 14 Analyst Ratings

Analysts' Consensus Price Target

$99.31
76.37% Upside
High Forecast$130.00
Average Forecast$99.31
Low Forecast$73.00
TypeCurrent Forecast
3/1/23 to 2/29/24
1 Month Ago
1/30/23 to 1/30/24
3 Months Ago
12/1/22 to 12/1/23
1 Year Ago
3/1/22 to 3/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$99.31$97.06$96.56$69.57
Predicted Upside76.37% Upside28.80% Upside25.94% Upside22.87% Upside
Get Exact Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.


EXAS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Exact Sciences Stock vs. The Competition

TypeExact SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside76.37% Upside1,854.11% Upside7.84% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/22/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$100.00 ➝ $90.00+50.53%
2/22/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
1/2/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$91.00+23.01%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.00+32.92%
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$95.00+44.99%
11/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$100.00 ➝ $90.00+34.37%
10/16/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$90.00 ➝ $80.00+19.67%
9/28/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$83.00+23.04%
8/3/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $110.00+26.51%
8/2/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$105.00 ➝ $110.00+14.06%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$75.00 ➝ $90.00-6.68%
8/2/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$99.00 ➝ $121.00+25.47%
6/22/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $120.00+26.25%
6/22/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $106.00+18.07%
6/22/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$95.00 ➝ $110.00+22.52%
6/22/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$100.00 ➝ $130.00+44.80%
5/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$73.00+10.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:02 AM ET.












EXAS Price Target - Frequently Asked Questions

What is Exact Sciences's consensus rating and price target?

According to the issued ratings of 14 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 2 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $99.31 with a high price target of $130.00 and a low price target of $73.00. Learn more on EXAS's analyst rating history.

Do Wall Street analysts like Exact Sciences more than its competitors?

Analysts like Exact Sciences more than other Medical companies. The consensus rating score for Exact Sciences is 2.86 while the average consensus rating score for medical companies is 2.68. Learn more on how EXAS compares to other companies.

Is Exact Sciences being upgraded by Wall Street analysts?

Over the previous 90 days, Exact Sciences's stock had 1 upgrade by analysts.

Does Exact Sciences's stock price have much upside?

According to analysts, Exact Sciences's stock has a predicted upside of 29.46% based on their 12-month stock forecasts.

What analysts cover Exact Sciences?

Exact Sciences has been rated by Benchmark, Canaccord Genuity Group, Guggenheim, William Blair, and Wolfe Research in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:EXAS) was last updated on 2/29/2024 by MarketBeat.com Staff